Hormone use: Studies suggest two years max The Philadelphia Inquirer Mon, 09 Feb 2009 06:01 AM PST Current guidance to use menopausal hormone therapy as briefly as possible should be interpreted to mean no more than two years because that's when breast-cancer risk rises, two new reports suggest. | Pregnancy Doesn't Worsen Breast Cancer WSB-TV 2 Atlanta Mon, 09 Feb 2009 05:59 AM PST About 10 percent of cases of breast cancer in women under 40 are found in pregnant women or new mothers. | Cannabis link to testicular cancer Adelaide Now Mon, 09 Feb 2009 05:52 AM PST YOUNG men who smoke marijuana are more likely to develop an aggressive form of testicular cancer than those who have never tried the drug, a study has found. | Study Says Pregnancy Doesn't Worsen Breast Cancer WYMT Mountain News Mon, 09 Feb 2009 05:50 AM PST The results for both recurring cancer or death among the study group was found to be the same as among women in the same age group who had not become pregnant. | Study: Smoking Pot Ups Risk of Testicular Cancer Fox News Mon, 09 Feb 2009 05:49 AM PST Marijuana use may increase the risk of developing testicular cancer, in particular a more aggressive form of the disease, according to a U.S. study published on Monday. | New cancer resource center opens WWMT 3 Kalamazoo Mon, 09 Feb 2009 05:42 AM PST KALAMAZOO, Mich. (NEWSCHANNEL 3) - A service starts Monday at Bronson Methodist Hospital to help ease the burdens of cancer on both patients and their families. | New cure for prostate cancer The Times of India Mon, 09 Feb 2009 05:30 AM PST SYDNEY: Scientists have developed a potential new treatment for prostate cancer, offering hope to thousands of patients. | Immunomedics Announces Second Quarter Fiscal 2009 Results GlobeNewswire via Yahoo! Finance Mon, 09 Feb 2009 05:30 AM PST MORRIS PLAINS, N.J., Feb. 9, 2009 -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenue of $8.5 million and net income of $2.9 million, or $0.04 per share, for the second quarter of fiscal year 2009, which ended December 31, 2008. | | |
|
No comments:
Post a Comment